Press Release: Biofrontera AG: Notice of First Quarter Results 2015

Biofrontera AG / Biofrontera AG: Notice of First Quarter Results 2015 . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Leverkusen, Germany, 22 May 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its results for the first three months period ending 31 March 2015 on 29 May 2015.

There is a conference call for shareholders and interested investors on 29 May 2015 at the following times:

9.00am CET (8.00am UK) conference call in German:

Dial-in number: +49-(0)69 271340800

Room number: 24938840#

10.00am CET (9.00am UK) conference call in English:

Dial-in number: +44 20336 45807

Room number: 52406056#

Ends

Enquiries, please contact:

Biofrontera AG +49 (0) 214 87 63 2 0 Prof. Hermann Lübbert, Chief Executive Officer press@biofrontera.com Thomas Schaffer, Chief Financial Officer www.biofrontera.com IR Germany: Brainwell Asset Solutions Jürgen Benker +49 (0) 152 08931514 Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs +44(0) 20 7408 4090 IR UK: Seton Services Toni Vallen +44(0) 20 7603 6797 Financial PR: Gable Communications +44(0) 20 7193 7463 John Bick +44 (0)7872 061007

Background:

The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz(R) , a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz(R) to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos(R) dermatological range of cosmetics. Belixos(R) products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos(R) cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Biofrontera AG via Globenewswire

HUG#1923569

--- End of Message ---

Biofrontera AG

Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Börse Berlin,

Freiverkehr in Bayerische Börse München,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Börse Düsseldorf;

http://www.biofrontera.com/ (END) Dow Jones Newswires

   May 22, 2015 10:18 ET (14:18 GMT)- - 10 18 AM EDT 05-22-15